Cell therapy for hepatitis B–related liver cancer
Part of Cancer, Infections clinical trials.
This Phase 1/2 study tests a lab-made cell treatment (SCG101) for people with hepatitis B–related liver cancer who have already had standard treatments. It aims to shrink tumors and improve outcomes in carefully selected patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have liver cancer (hepatocellular carcinoma) proven by biopsy or fluid test
- Your liver cancer is related to hepatitis B, and your blood tests match the study pattern (HBeAg negative, HBsAg positive, HBV-DNA not too low)
- You have had at least two standard whole-body (systemic) treatments for liver cancer
- You have a tumor stage that is B or C (BCLC stage B/C) and good enough liver function (Child-Pugh score 7 or less)
- Your genetics include HLA-A*02, and you can have at least one measurable tumor spot on scan
- You do not have certain conditions like other cancers, brain/spread to the brain, uncontrolled immune disease needing strong immune suppression, or HIV
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests a lab-made immune cell treatment that targets hepatitis B (HBV)–related liver cancer. It may help by directing the body’s immune system to attack the cancer, while carefully checking safety.
This study tests a new cell therapy (called CG-102-12C) for advanced liver cancer that has a specific marker (GPC3) and has stopped responding to standard treatments. The therapy uses your own immune cells, specially trained to attack the cancer. This might be an option if you have tried other treatments and they no longer work or cause bad side effects.
This trial tests a new immune cell therapy (LioCyx-M) for people with advanced liver cancer caused by hepatitis B. It uses specially designed T cells (a type of immune cell) that target the hepatitis B virus and may help fight the cancer.
This trial tests a two-drug combination to treat chronic hepatitis B in people who have had liver cancer surgery or ablation. It aims to reduce the virus and improve liver health.
This Phase 1 study tests a stem cell product to see if it is safe and how it affects people with worsening hepatitis B-related cirrhosis. It may help researchers understand whether the treatment could improve liver function in this stage of illness.
This trial studies an experimental cell therapy that uses your own immune cells collected from your tumor to fight the cancer. It aims to see if this approach is safe and effective for advanced liver cancer that has progressed after standard treatments.
Hear when a new Hepatocellular Carcinoma Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.